Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.68 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.58 |
| ▸ | RELA | Q04206 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.57 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5121065 | 0.89 | ALOX5 (0.66) | F2RL1ALDH1A1POLBALOX5CALM1 | |
| SCHEMBL11830150 | 0.87 | ALOX5 (0.59) | F2RL1ALDH1A1POLBALOX5CALM1 | |
| SCHEMBL9663990 | 0.86 | ALOX5 (0.58) | F2RL1POLBALOX5CALM1 | |
| SCHEMBL6480428 | 0.84 | CYP1A2 (0.74) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL7329940 | 0.84 | F2RL1 (0.85) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL9135914 | 0.83 | FFAR1 (0.50) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL274471 | 0.82 | FFAR1 (0.81) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL30792366 | 0.82 | FFAR1 (0.81) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL2468017 | 0.82 | SMN1; SMN2 (0.72) | F2RL1FFAR1ALDH1A1POLBNFKB1 | |
| SCHEMBL27383073 | 0.82 | F2RL1 (0.70) | F2RL1FFAR1ALDH1A1POLBNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116836153-B | CDK9-Cyclin T1 protein interaction inhibitor and application thereof | 厦门大学 | 2026-05-19 | — | — | CN | disclosed |
| US-20250282732-A1 | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2025-09-11 | — | — | US | disclosed |
| US-20250282733-A1 | NOVEL 1,2,3,4,4A,5,6,7,8,9,10,10A-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2025-09-11 | — | — | US | disclosed |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2025-08-07 | — | — | US | disclosed |
| CN-119053585-A | Novel 1,2,3, 4a,5,6,7,8,9,10 a-dodecahydrobenzo [ G ] quinolin-6-ol ester compounds and uses thereof | 综合研究实验室瑞典股份公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240327427-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | NEURODON CORPORATION | 2024-08-22 | — | — | US | disclosed |
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | NEURODON CORPORATION (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024050825-A1 | COMPOUNDS AS MLKL INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
| US-4861798-A | Lipoxygenase inhibitory compounds | BRISTOL-MYERS COMPANY (US) | 1989-08-29 | — | — | US | disclosed |
| EP-0326364-A2 | Renin inhibitory oligopeptides, their preparation and use | Sankyo Company Limited (JP) | 1989-08-02 | — | — | EP | disclosed |
| EP-0302603-A1 | Dopamine-beta-hydroxylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 1989-02-08 | — | — | EP | disclosed |
| US-4798843-A | HYPOTENSIVE AGENTS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-17 | — | — | US | disclosed |
| EP-0273451-A2 | Lipoxygenase inhibitory compounds | Bristol-Myers Squibb Company (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0251077-A1 | Tetrahydrobenzothiazoles, their preparation and use | BOEHRINGER INGELHEIM KG (DE) | 1988-01-07 | — | — | EP | disclosed |
| US-4717724-A | FUNGICIDES, ANTIPROTOZOA, BACTERICIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-01-05 | — | — | US | disclosed |
| US-4536346-A | TREATMENT OF ATHEROSCLEROSIS | AMERICAN CYANAMID COMPANY (US) | 1985-08-20 | — | — | US | disclosed |
| EP-0124791-A1 | Aralkanamidophenyl compounds | AMERICAN CYANAMID COMPANY (US) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11992487-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | F2RL1 4274/4885FFAR1 1529/4885ALDH1A1 1661/4885 |
| US-12144806-B2 | Quinolines that modulate SERCA and their use for treating disease | ATP2A1, ATP2A3, ATP2A2 | F2RL1 4274/4885FFAR1 1529/4885ALDH1A1 1661/4885 |
| US-20250248990-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | F2RL1 4274/4885FFAR1 1529/4885ALDH1A1 1661/4885 |
| US-20240277694-A1 | QUINOLINES THAT MODULATE SERCA AND THEIR USE FOR TREATING DISEASE | ATP2A1, ATP2A3, ATP2A2 | F2RL1 4274/4885FFAR1 1529/4885ALDH1A1 1661/4885 |
| US-20250282732-A1 | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF | UGT2B7, CYP4B1, UGT1A7 | F2RL1 4648/4885FFAR1 1697/4885ALDH1A1 227/4885 |
| US-20250282733-A1 | NOVEL 1,2,3,4,4A,5,6,7,8,9,10,10A-DODECAHYDROBENZO[G]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF | UGT1A1, CYP1B1, CYP4B1 | F2RL1 4439/4885FFAR1 3622/4885ALDH1A1 133/4885 |
| US-20240327427-A1 | NEW COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PSEN2, PSEN1, CHAT | F2RL1 2790/4885FFAR1 3185/4885ALDH1A1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.